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a B S t r a c t
Polycystic ovary syndrome (PcOS) is the most frequent endocrine disorder in women and it is associated with an in-
creased rate of infertility. its etiology remains largely unknown, although both genetic and environmental factors play 
a role. PCOS is characterized by insulin resistance, metabolic disorders and low-grade chronic inflammation. To date, 
the treatment of PcOS is mainly symptomatic and aimed at reducing clinical signs of hyperandrogenism (hirsutism and 
acne), at improving menstrual cyclicity and at favoring ovulation. Since PcOS pathophysiology is still largely unknown, 
the therapeutic interventions currently in place are rarely cause-specific. In such cases, the therapy is mainly directed at 
improving hormonal and metabolic dysregulations typical of this condition. diet and exercise represent the main envi-
ronmental factors influencing PCOS. Thus, therapeutic lifestyle changes represent the first line of intervention, which, in 
combination with oral contraceptives, represent the customary treatment. insulin resistance is becoming an increasingly 
studied target for therapy, most evidence stemming from the time-honored metformin use. relatively novel strategies 
also include the use of thiazolidinediones and GLP1-receptor agonists. in recent years, a nutraceutical approach has 
been added to the therapeutic toolkit targeting insulin resistance. indeed, emerging data support inositol and alpha-lipoic 
acid as alternative compounds, alone or in combination with the aforementioned strategies, with favorable effects on 
ovulation, insulin resistance and inflammation. Nevertheless, additional studies are required in adolescents, in order to 
assess the effectiveness of diet supplements in preventing negative impacts of PcOS on fertility in adult age. this review 
focuses on the main therapeutic options for PcOS to date.
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Polycystic ovary syndrome (PcOS) is a het-erogeneous clinical condition, which is con-
sidered the most frequent endocrine disorder in 
women of reproductive age. its etiology remains 
unknown, although there is evidence that both 
genetic and environmental factors may contrib-
ute to its origin.1 according to current diagnos-
tic criteria for adult women, established in a 
joint consensus workshop of the european Soci-
ety for Human reproduction and embryology 
(eSHre) and the american Society for repro-
ductive Medicine (aSrM), held in rotterdam in 
2003, PcOS may be diagnosed by the presence 
of at least two of the following three clinical fea-
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genemic versus normoandrogenemic subjects, 
as many as 30% of women with PcOS.9 assess-
ment of ovarian morphology is another prob-
lematic issue. in particular, it has been argued 
that the cut-off value for distinguishing an ab-
normal follicle count should be adapted accord-
ing to available probes, from the traditional fig-
ure of 12, indicated by the rotterdam workshop, 
up to 25 when using modern technology provid-
ing greater resolution, with a transducer fre-
quency ≥8 MHz.10 To overcome these difficul-
ties, measurement of serum anti-Müllerian hor-
mone (aMH), which is directly associated with 
follicle count and is increased in many women 
with PcOS, has been proposed as a potential al-
ternative to assess ovarian morphology on ultra-
sound.11 However, this assay still needs adequate 
standardization. Diagnostic difficulties are even 
more relevant in adolescents, due to the physio-
logical presence in these subjects of features that 
mirror some clinical aspects of PcOS. in par-
ticular, many girls exhibit a condition of tran-
sient anovulation. it has been reported that more 
than 80% of cycles are anovulatory during the 
first year after menarche, and 25% remain dys-
functional in the sixth year.12 PcOm as well may 
be physiological in adolescents. this morpholo-
gy was reported in one third of healthy girls 4 
years after menarche, without any relationship 
to the metabolic and endocrine features of 
PcOS.13 nevertheless, while it was hypothe-
sized that isolated PcOm may anticipate ovarian 
dysfunction in some girls, anovulatory adoles-
cents can show subtle endocrine alterations,14 
suggesting a potential propensity to develop-
ment of overt PcOS later in life. it has been sug-
gested that age-specific cut-off values for ovari-
an follicle number should be defined in adoles-
cents.15 However, transvaginal imaging cannot 
be performed in many girls, with limitations in 
ovarian morphology assessment, especially in 
obese individuals. in this regard, when using 
transabdominal ultrasound, reporting may be 
best centered on ovarian volume, maintaining a 
threshold of ≥10 mL, given the difficulty of con-
sistently measuring follicle number. Finally, hir-
sutism may require time to develop, whereas 
acne is a very common feature in young ages, 
making it often difficult to diagnose clinical hy-
tures: clinical and/or biochemical hyperan-
drogenism, chronic oligo-anovulation, and the 
micro-polycystic morphology of the ovary 
(PcOm).2 nevertheless, no alterations are spe-
cific to PCOS, and other disorders that can po-
tentially cause these abnormalities, such as late-
onset congenital adrenal hyperplasia, hyperpro-
lactinemia or androgen-secreting tumors, must 
be preliminary excluded. therefore, PcOS is an 
exclusion diagnosis. it has been estimated that 
PcOS, as diagnosed by the rotterdam criteria, 
may occur in about 10% of women of reproduc-
tive age,3 but this figure could be even higher.4, 5 
indeed, available epidemiologic data are limited 
and prevalence estimates may be influenced not 
only by the diagnostic criteria but also by the 
methods used for assessing these aspects as well 
as by the ethnic characteristics of the population 
investigated. in particular, hirsutism, which is 
the more frequent and specific clinical feature of 
hyperandrogenism, is strongly affected by con-
stitutional and ethnic factors. in this regard, the 
cut-off value for diagnosing excessive body hair 
growth when using the usually adopted method, 
i.e. the modified Ferriman-Gallwey score, is 
generally 8 for caucasian, Middle-eastern or 
afro-american women, but it may be just 3 for 
Far-east asian women.6 Other clinical features, 
such as acne and scalp hair loss, are less specific 
and cannot be considered signs of hyperan-
drogenism, when androgen levels are normal 
and there is no hirsutism. However, acne can be 
found in 15-25% and scalp hair loss in 20-30% 
of adult women with PcOS. acne is a common, 
complex, multifactorial process in which andro-
gens play a central role, but other factors are re-
quired.7 conversely, there is not an obligate link 
between androgen action and female pattern hair 
loss, which may be present even in women lack-
ing an androgen receptor. nevertheless, in many 
women with hair loss androgen action in the 
scalp may be enhanced, and assessment of a 
possible androgen excess is required.8 Unfortu-
nately, assessment of biochemical hyperan-
drogenism can also be challenging, being ham-
pered by significant limitations of methods for 
assaying serum androgens generally used in 
clinical labs. indeed, ordinary methods may 
misclassify, when distinguishing hyperandro-
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arche, girls can be considered at risk for PcOS, 
suggesting a clinical and possibly ultrasono-
graphic and/or aMH follow up. in these cases, 
risk of overdiagnosis and unnecessary interven-
tions should be balanced against the individual 
need of a diagnosis and early therapy.20 notably, 
no current definitions of PCOS include obesity 
or insulin resistance (ir) among the diagnostic 
criteria. nevertheless, these are common fea-
tures of PCOS women and may play a signifi-
cant role in the pathophysiology of the syn-
drome. a meta-analysis of available studies con-
cluded that body fat excess may be found in up 
to 60% of PcOS subjects, often with a central 
distribution of adipose tissue.21 a similar per-
centage (58%) was reported in the cohort of the 
verona 3P Study,22 which includes a large series 
of consecutive women with PcOS. However, 
we must consider that a referral bias could pro-
duce an overestimation of these percentages. in 
actual fact, a comparison of referral women with 
PCOS with those identified through the screen-
ing of an unselected population suggested that 
frequency of obesity might indeed be similar in 
PcOS women and in the background popula-
tion, although contributing to worsening the 
whole clinical picture of these patients.23 a body 
of evidence indicates that ir is a common fea-
ture of PcOS independently of obesity, although 
it is not universal in these patients. in particular, 
it was estimated that 70-75% of women with this 
condition have impaired insulin action, as as-
sessed by the gold standard glucose clamp tech-
nique.24, 25 interestingly, these studies showed 
that a higher Body Mass index (BMi) exacer-
bates the reduction of insulin sensitivity, which 
is characteristic of PcOS, also suggesting a 
greater impact of body fat excess in PcOS than 
in controls.25 an important point is that ir and 
the associated hyperinsulinemia may contribute 
to the origin of PcOS by different mechanisms, 
including increased androgen production by 
both the ovary and the adrenal,26, 27 and possibly 
by reducing sex hormone binding globulin 
(SHBG) synthesis in the liver.28 However, the 
mechanisms underlying the PCOS-specific im-
pairment of ir remain poorly understood.29 an-
other important issue is that the adoption of the 
rotterdam diagnostic criteria has generated, un-
perandrogenism. Therefore, while the definition 
of PcOS in adolescents should follow the gen-
eral laws established for adult women, diagnos-
ing the presence of ovarian dysfunction and 
clinical hyperandrogenism may be a problemat-
ic issue in young girls, and no unanimously ac-
cepted criteria for diagnosing PcOS in adoles-
cence exist. eSHre and aSrM, in a consensus 
workshop held in amsterdam in 2010, proposed 
that the presence of all three elements of the 
rotterdam criteria is needed in teenagers to di-
agnose PcOS. in particular, these guidelines 
suggested that menstrual dysfunction should be 
present for at least 2 years after menarche; the 
diagnosis of PcOm on ultrasound should be 
based on increased ovarian size (>10 cm3); and 
hyperandrogenemia rather than clinical signs of 
androgen excess should be documented.16 con-
versely, the endocrine Society suggested that 
the diagnosis of PcOS in adolescents should 
rely on a complete clinical picture, including 
clinical evidence of androgen excess, increased 
androgen levels and persistent oligomenorrhea, 
after exclusion of secondary causes.17 notably, 
according to the international PcOS network, 
irregular menstrual cycles cannot be diagnosed 
in the first year post menarche, whereas they 
should be defined as <21 or >45 days in the pe-
riod 1 to <3 years post menarche, and <21 or 
>35 days thereafter, while primary amenorrhea 
can be established by age 15 or at least 3 years 
after thelarche.18 More recently, an international 
consortium of Paediatric endocrinology update 
has concluded that appropriate diagnosis of ado-
lescent PcOS requires the presence of both 
menstrual irregularities, 2 years beyond men-
arche, and evidence of biochemical and/or clini-
cal hyperandrogenism, in particular progressive 
hirsutism, after exclusion of other disorders. ac-
cording to these authors, severe cystic acne and 
PcOm represent supportive elements, but only 
in concert with the main features.19 Finally, oth-
er experts recently suggested that PcOS diagno-
sis should be considered in adolescents with per-
sistence of oligomenorrhea 3-4 years after men-
arche, in the presence of clinical and/or bio-
chemical hyperandrogenism and after exclusion 
of other disorders. However, when menstrual 
dysfunction persists up to 2 years after men-
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sidered. customary treatment of these subjects 
is generally represented by combined hormonal 
contraceptives, which can induce regular men-
ses and improve symptoms of hyperandrogen-
ism, in particular of hirsutism and acne, also 
protecting from endometrial hyperplasia. How-
ever, efficacy on hirsutism is limited,6 and there 
is no clear evidence of beneficial effects of this 
therapy on ir and the associated metabolic al-
terations. In addition, there may be specific 
contraindications in subjects at risk for throm-
boembolic and cardiovascular events. these 
general considerations are also true for adoles-
cents with PcOS,19, 20 although cardiovascular 
events are extremely rare in girls. notably, most 
knowledge on the long-term effects of Oc de-
rives from observational studies in the general 
population, whereas studies in PcOS women 
are very limited and short-term and there are no 
rcts on these aspects.37 in order to counteract 
the mechanisms potentially underlying the ori-
gin of PcOS and the associated metabolic ab-
normalities, and potentially also to prevent some 
long-term complications of this condition, strat-
egies aimed at improving ir have been assessed, 
especially with the insulin sensitizer metformin. 
these studies reported some interesting short-
term findings, in terms of effects on reproduc-
tive and metabolic alterations.38 combined 
therapy with hormonal contraceptive and met-
formin has also been proposed, although clinical 
experience is still limited.39 Finally, recent find-
ings have suggested that novel strategies, such 
as incretin mimetic drugs, may be of potential 
interest for people with PcOS.40 the following 
sections will discuss these different therapeutic 
options for women with PCOS, with specific at-
tention to their use in adolescents.
Lifestyle intervention modifications
Environmental factors significantly impact on 
genetic predisposition to PcOS. to date treat-
ment is symptomatic, although lifestyle changes 
can dramatically affect phenotype, and a first-
line intervention is represented by lifestyle 
changes, in particular, weight loss and preven-
tion of weight gain strategies (table i).41-47 co-
chrane reviews support lifestyle interventions 
der the common label of PcOS, distinct clinical 
“phenotypes” of the syndrome, based on the dif-
ferent possible combinations of diagnostic fea-
tures in each individual patient. a recent niH 
workshop on PCOS, while confirming the Rot-
terdam criteria for diagnosis, has recommended 
distinguishing women with the following phe-
notypes: androgen excess + ovulatory dysfunc-
tion + PcOm (complete phenotype); androgen 
excess + ovulatory dysfunction (classic pheno-
type); androgen excess + PcOm (ovulatory phe-
notype); and ovulatory dysfunction + PcOm 
(normoandrogenic phenotype).30 interestingly, 
there is a scale of metabolic risk among these 
different phenotypes. in particular, women with 
both hyperandrogenism and ovulatory dysfunc-
tion, with or without PcOm, and, to a lesser ex-
tent, those with the ovulatory phenotype appear 
to be characterized by ir and the associated ab-
normalities, whereas those with the normoan-
drogenic phenotype do not.31 it is also notewor-
thy that androgen excess, in turn, may contribute 
to generating hyperinsulinemia, not only by al-
tering insulin action,32, 33 but possibly also by 
impairing the metabolic clearance of insulin.34, 35 
therefore, there is evidence of a vicious circle 
between ir and hyperandrogenism in these 
women. Metabolic syndrome is another altera-
tion that can be found with higher frequency in 
women with PcOS.31 interestingly, this altera-
tion may be found even in many adolescents 
with this syndrome.36
Goals of therapy in women with PCOS
the main complaints of individuals with PcOS 
are generally menstrual abnormalities, clinical 
signs of hyperandrogenism and, in adult wom-
en, infertility.1, 2 therapy of PcOS is tradition-
ally based on a symptomatic approach, which 
largely depends on the perceived individual 
needs of patients. However, while these should 
be carefully taken into account by physicians, 
current knowledge of the pathophysiology of the 
syndrome and its long-term potential sequelae 
suggests that other aspects, such as body fat ex-
cess, metabolic alterations, and risk of endome-
trial hyperplasia and endometrial cancer and of 
psychological disturbances should also be con-
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waist-to-hip ratio (WHr), weight, fat mass and 
triglyceride levels decreased significantly and 
high-density lipoprotein (HdL)-cholesterol in-
creased. However, no change was reported in 
low-density lipoprotein cholesterol (LdL-c), 
very low-density lipoproteins (vLdL), and to-
tal cholesterol concentrations.43 Systematic re-
views highlight the relevance of quality of life 
for the health of PcOS women. the effects of 
LSM interventions, including exercise-only, 
diet-only, exercise and diet on health-related 
quality of life or general quality of life were 
structurally and systematically analyzed.49 an 
identified lifestyle factor that adversely affected 
health and reproductive outcomes in PcOS was 
smoking since cigarette smoke components had 
a negative impact on the follicular milieu and 
affected hormone concentrations in the luteal 
phase. Psychological stress effects are not ful-
ly understood, because it is hard to distinguish 
whether stress is a contributor or an effect of 
PCOS. Furthermore, stress is quite difficult to 
define and measure and common guidelines are 
still needed. caffeine may have adverse effects 
on fertility, affecting ovulation and corpus lu-
teus by changing hormonal levels. alcohol con-
sumption is associated with fertility reduction 
and weight gain. chemicals and pollutants may 
negatively affect fertility. recreational drugs 
are currently taken by some young women and 
may result into adverse effects on fertility, al-
for PcOS, nevertheless the behavioral compo-
nents of these interventions are not yet fully un-
derstood and defined.48 the main environmen-
tal factors influencing this syndrome are diet 
and exercise. The evidence of the influence of 
lifestyle modification (LSM) interventions on 
clinical, hormonal and metabolic profiles have 
been analyzed in several systematic reviews and 
meta-analyses hereafter reported. randomized 
controlled trials (rcts) have compared PcOS 
women of ages ranging from 18 to 32 years re-
ceiving LSM interventions, to women receiving 
none or minimal interventions or metformin. 
LSM significantly decreased fasting blood glu-
cose (FBG) and fasting insulin concentrations, 
and these changes were associated with BMi 
improvement. LSM showed better results than 
metformin in improving glucose or insulin lev-
els whereas the effect on hirsutism measured us-
ing the Ferriman-Gallwey score was unclear.41 
a descriptive-comparative study compared 65 
women with PcOS with 65 healthy women col-
lecting data by means of questionnaires for diet, 
physical activity and unhealthy behaviors con-
cluding that a significant association between 
PcOS and hypercaloric diet, and scarce physical 
activity was evident, but there was no associa-
tion between PcOS and unhealthy behavior.42 
another study compared PcOS women under-
going an aerobic exercise program with a control 
group: at the end of the exercise program, BMi, 
Table I.— Main findings relative to the effects of lifestyle intervention modifications in PCOS.41-47
Study Main results
domecq et al. (2013)41 decreased fasting glucose and fasting insulin concentrations associated with BMi improvement
effect on hirsutism unclear
Sedighi et al. (2014)42 Hypercaloric diet, and scarce physical activity associated with PcOS
no association of PcOS with unhealthy behaviors
abazar et al. (2015)43 aerobic exercise decreased BMi, WHr, weight, fat mass and triglyceride levels and increased HdL-
cholesterol
norman et al. (2006)44 Psychological Stress: effects not fully understood
caffeine: adverse effects on fertility
alcohol consumption: associated with fertility reduction and weight gain
chemicals and pollutants: may negatively affect fertility
recreational drugs: adverse effects on fertility
Patel et al. (2018) 45 Balanced diet and regular and moderate physical exercise are strongly recommended
Brennan et al. (2017)46 Weight management in association with behavioral and psychological strategies especially in 
reproductive age are recommended
cappelli et al. (2017)47 additional interventions consisting in nutritional supplements or drug administration and/or surgery 
are needed when weight recovery occurs following appropriate diet and physical exercise practice
BMi: Body Mass index; WHr: waist-to-hip ratio; HdL: high-density lipoprotein.
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Oc (such as dienogest, drospirenone and norges-
timate) show anti-androgenic properties (andro-
gen receptor antagonism, inhibition of 5 alpha 
reductase activity). the progestins contained in 
third generation contraceptives show a low an-
drogenic activity.53 despite medical societies 
recommend the use of Oc in adult women with 
PcOS,16, 17, 50 definite conclusions regarding in-
dications, long term risks and safety in adoles-
cents have not been drawn as current evidence 
is derived from studies with low methodologi-
cal quality. the only available meta-analysis of 
rcts regarding treatment of PcOS in adoles-
cents was published by the group of al Khali-
fah54 where Oc were compared with metformin. 
the authors included four rcts which enrolled a 
total of 170 patients. Statistical analysis showed 
an overall mild improvement in menstrual cycle 
frequency and in acne scores in patients treated 
with Oc versus metformin. conversely, the use 
of metformin was associated with a significant 
reduction in BMi, total cholesterol, LdL choles-
terol and rate of dysglycemia. interestingly, the 
impact on hirsutism was similar in patients treat-
ed with metformin compared to Oc. However, 
the authors evidenced that the results should be 
interpreted carefully because of the very low to 
low quality of evidence of the studies included. a 
more recent meta-analysis on an adult population 
including 33 studies and 1521 patients suggested 
a significant effect in favor of OC in terms of hir-
sutism scores, when severe hirsute patients were 
excluded, while it confirmed a superiority of OC 
in terms of menstrual cycle regularity.39 When as-
sessing quality of life, Oc seemed to have bene-
ficial effect in PCOS patients, at least when asso-
ciated with lifestyle intervention. a study by the 
group of Harris-Glocker55 reported an improve-
ment of all the variables related to quality of life, 
assessed with a specific questionnaire, in obese 
adolescent with PcOS enrolled in a lifestyle 
program and taking Oc. With regard to safety, 
several studies have examined the impact of Oc 
on glucose and lipid metabolism, cardiovascular 
risk and venous thromboembolism (vte) risk in 
PcOS patients. evidence on glucose and lipid 
metabolism are conflicting, and some studies 
suggest differences related to the population en-
rolled and the type of pill used. a meta-analysis 
though data are scarce and uncertain.44 a holistic 
review on PCOS as an inflammatory, systemic 
and endocrine disease suggests that extreme ex-
ercise and drastic dieting may have negative ef-
fects on human body, which is sensitive to high 
energy-fluctuations. Therefore, a balanced diet 
and regular and moderate physical exercise are 
strongly recommended.45 Finally, an interesting 
narrative review highlighted the relevance of 
supporting in clinical routine practice LSM for 
weight management in association with behav-
ioral and psychological strategies especially in 
reproductive age. these authors provided also 
a list of key recommendations for weight man-
agement interventions for PcOS women.46 al-
though the gold standard practice for improving 
insulin sensitivity in obese PcOS women to date 
consists in weight management by means of ap-
propriate diet and physical exercise, about 90% 
of these patients experience a weight recovery. 
therefore, in particular in these cases, additional 
interventions consisting in nutritional supple-
ments or drug administration and/or surgery are 
sometimes needed.47
Oral contraceptives
in patients with diagnosis of PcOS, there are 
several treatment options depending on the ma-
jor clinical manifestations. non-pharmacological 
treatment (lifestyle interventions such as physi-
cal activity, diet and caloric restriction) are con-
sidered the first line approaches in overweight 
and obese patients and in patients with metabolic 
disturbances. as stated in a separate section of 
this review, in these patients, treatment with 
metformin or other insulin sensitizers can be an 
option. in cases with hirsutism and menstrual ir-
regularity as main clinical issues, pharmacologi-
cal agents may be used. in these patients, oral 
contraceptives (OC) are the first line pharmaco-
logical approach.50
Oc reduce hyperandrogenemia manifesta-
tions and regulate menstrual cycle. these ac-
tions depend on a suppression of pituitary go-
nadotropin secretion51 and on an increase in sex 
hormone binding globulin concentrations with 
a subsequent reduction in free serum androgen 
levels.52 Moreover, progestins contained in some 
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tions for Oc goes beyond the purpose of this 
review. On this topic, we recommend referring 
to World Health Organization medical eligibility 
criteria for contraceptive use.62 despite the limit-
ed number of high-quality studies regarding risk 
of gynecological cancer in PcOS, data from the 
literature suggest an increased risk of endome-
trial cancer in these patients, while data regard-
ing ovarian cancer are contradictory. in addition, 
epidemiological data indicate no relationship 
between PcOS and breast cancer.63 considering 
the lack of specific evidence regarding the im-
pact of Oc use in PcOS patients and cancer risk, 
it is reasonable to report data on general popula-
tion to comment on safety of these medications 
in PcOS patients. endometrial cancer risk is re-
duced by Oc use, as strongly suggested by the 
literature.64, 65 Oc use is protective also for ovar-
ian cancer with persistence in risk reduction for 
more than 30 years after Oc discontinuation.66, 67 
data on breast cancer risk in Oc users indicates a 
mild increased risk for this tumor, with an attrib-
utable risk of +3%. the increased risk appears 
to be limited to women who are currently using 
or have recently used these medications, with 
progressive reduction with time of excessive risk 
and a rate comparable to the general population 
after at least 10 years of discontinuation.68 Over-
all, whereas Oc use is associated with an in-
creased risk of breast cancer, total cancer risk ap-
pears to be reduced in most relevant studies, due 
to the protective effect on endometrial, ovarian 
and colorectal cancer.64, 66, 69 Oc have different 
dosages and types of oestrogens which should be 
associated with different kinds of progestins. in 
adolescents with PcOS the choice of Oc must be 
individualized for each patient following differ-
ent considerations. SHBG levels are influenced 
differently by different types of oestrogens. in 
turn, oestrogens can decrease serum concentra-
tions of free testosterone (t).52 Several studies 
show that ethinyl estradiol (ee) has a greater ac-
tion in increasing SHBG levels than natural es-
tradiol.70 Furthermore, progestins have different 
binding affinity for progesterone receptors sup-
pressing gonadotropin release and subsequently 
decreasing ovarian androgen synthesis.71 in 
PcOS patient with acne and hirsutism proges-
tins, as nogestimate, drospirenone, desogestrel 
published by the group of Halpering56 evaluat-
ing prospective cohorts and rcts that enrolled 
women, aged 13–44 years with PcOS on Oc 
for at least three months, showed no changes in 
FBG, insulin and homeostatic model assessment 
of ir (HOMa-ir) related to these medications. 
conversely, the authors showed that Oc were 
associated with an increase in triglycerides and 
HdL cholesterol levels. Similarly, a more recent 
meta-analysis by amiri et al.57 on 27 studies, 
including adults and adolescents with PcOS, 
reported that the use of Oc was not associated 
with significant change in BMI, FBG or HOMA-
ir but long term use of these medications was 
found to worsen the lipid profile (increase in 
total, HdL and LdL cholesterol and increase in 
triglycerides). it is important to underline that 
both studies are limited by the heterogeneity 
of results and by lifestyle interventions that pa-
tients with PcOS received during the follow-up 
period. Moreover, most of participants were not 
obese and it is therefore difficult to generalize 
these results to different subgroups of PcOS pa-
tients. Overall, the results of these studies sug-
gested no significant change in glucose metabo-
lism and modest worsening of the lipid profile. It 
is therefore reasonable to check periodically the 
metabolic profile in PCOS patients on OC and 
to use low estrogen formulations in patients with 
known dyslipidemia.37 the overall impact of Oc 
on cardiovascular health is debated as well, with 
some authors suggesting that, for PcOS patients, 
lowering serum androgens with improvement in 
endothelial and adipocyte function may counter-
act the mild increase in triglycerides and choles-
terol levels.58 a major known side effect of Oc is 
increased risk of thromboembolism.59 PcOS pa-
tients present impaired fibrinolysis and abnormal 
endothelial function,60 with higher risk of vte 
compared to the general population. the group 
of Bird showed how women with PcOS not tak-
ing Oc have a 1.5-fold increased risk of vte. 
the relative risk rises to 2-fold increase in PcOS 
patients on Oc.61 For this reason, a thorough 
personal and family history of thromboembolic 
events and a careful assessment of all other car-
diometabolic risk factors needs to be addressed 
when considering starting the treatment with Oc 
in PcOS patients. discussing the contraindica-
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the breakdown of energy stores, which, in turn, 
reduce the hepatic glucose output84 and, con-
comitantly, increase hepatic insulin sensitivity.85 
Metformin also suppresses lipolysis and lipogen-
esis in the adipose tissue, thus improving the li-
pidic and glycemic toxicity burden to the insulin-
mediated glucose uptake in the skeletal muscle.84 
With regard to the effects of metformin on andro-
gen levels, it is estimated that metformin reduces 
circulating t levels by approximately 20-25%,81 
primarily as a consequence of reduced hyperin-
sulinemia.82, 83 importantly, such effect occurs 
early after metformin initiation and before any 
noticeable change in individual insulin sensi-
tivity, thus suggesting possible direct effects of 
metformin at the ovarian level.86, 87 Support-
ing evidence of such an effect stems from data 
obtained in cultured human thecal cells, where 
exposure to metformin led to decreased ste-
roidogenesis secondary to inhibition of the mi-
tochondrial respiratory chain that subsequently 
would reduce 3β-hydroxysteroid dehydrogenase 
type 2 (HSD3B2) and 17α-Hydroxylase/17,20 
lyase (cYP17a1) activity, which is reported to 
be overexpressed in PcOS.88, 89 the question as 
to whether metformin, alone or in combination 
with other insulin sensitizing drugs, exerts ben-
eficial effects on fertility in women with PCOS 
has been thoroughly investigated in at least two 
large meta-analyses of randomized clinical trials. 
However, results were not conclusive.38 Similar 
lack of benefit has been reported also with re-
gard to the treatment of acne and hirsutism.90 in 
summary, the use of metformin in adult women 
is supported by international guidelines for the 
treatment of the metabolic disturbances under-
lying PcOS,17 i.e. altered glucose tolerance in 
women with (pre)diabetes and comorbid PcOS 
and in those with PcOS that are at high risk 
of developing diabetes because of ethnic back-
ground and/or genetic/familial predisposition.91 
in contrast, the effects on body composition and 
weight loss are not so robust and are not current-
ly supported by solid data to support inclusion 
in treatment guidelines. On top of that, it should 
also be pointed out that no firm evidence cur-
rently exists in adolescents, although a limited 
number of trials are currently ongoing or await-
ing completion,92, 93 as reported in table ii.92-96 
and cyproterone acetate, are first choice since 
they have an antiandrogenic action.72 in partic-
ular, cyproterone acetate seems to be more ef-
fective than drospirenone in increasing SHBG 
levels.73 However, Ocs containing cyproterone 
should be avoided in the adolescent subjects ow-
ing to undesirable effects on lipid profile and 
glucose metabolism.74-76 in one study, 20 µg ee 
combined with 3 mg drospirenone were effective 
as 30 µg ee in improving clinical and hormonal 
parameters of lean PcOS women, while they 
showed a moderate impact on the lipid profiles. 
nevertheless, both doses improved hirsutism, t, 
dehydroepiandrosterone-sulfate (dHea-S), and 
SHBG levels.77
Metformin
it is estimated that ir is associated with 50-70% 
of PcOS cases, although the prevalence of ir 
widely changes according to the measurement 
methods employed.78 as described above PcOS 
is a heterogeneous disorder characterized by 
varying degrees of ir which have hormonal and 
metabolic effects independent of BMi and glu-
cose tolerance state.79 indeed, the co-existence of 
a higher BMi in PcOS subjects with ir further 
exacerbates such effects, thus leading to the in-
creased cardiometabolic risk and worsening de-
grees of hormonal and reproductive disorders.25 
Most importantly, it appears that the metabolic 
abnormalities characterizing overt PcOS take 
place early in life, with adolescents affected by 
PcOS displaying higher degrees of (hepatic) ir, 
as compared with their BMi-matched counter-
parts without PcOS.80 Metformin exerts pleio-
tropic effects on several tissues, including the 
liver, skeletal muscle and adipose tissue. recent 
evidence also supports both direct and indirect 
effects on ovarian steroidogenesis.81 the earliest 
data of an insulin-sensitizing effect of metformin, 
with a concomitant reduction in serum t levels 
and increased SHBG, were reported by nestler 
et al.82, 83 the improvement of insulin sensitivity 
by metformin is primarily due its effects on the 
liver, as metformin activates the cellular energy 
sensor adenosine monophosphate-activated pro-
tein kinase (aMPK) and reduces the expression 
of gluconeogenic enzymes. these events lead to 
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Table II.— Double-blinded randomized clinical trials of insulin sensitizing drugs and GLP-1 RA conducted in ado-
lescents/young adults with PCOS over the last decade.92-96
Study Subjects drug comparator Main results nct
Ladson (2011)93 Overweight/obese 
adolescents and young 
adults with PcOS
n.=114; age: 29.0±5.4 
years; BMi at baseline: 
38.0±8.0 kg/m2
PCOS definition: 1990 
niH criteria




intervention as in 
Knowler et al.97
Placebo + lifestyle 
intervention (150 
min/wk exercise 
combined with a 
low-calorie diet: 
≥7% weight loss 
goal)
Only 38 completed the study; 
drop-out rate: 66.7%
No significant difference in 
ovulation rates or iSi
testosterone levels 
significantly lower compared 
with baseline in the 
metformin group at 3 months, 
but not at 6 months
no differences in weight 
loss between groups, but 
significant weight change 
from baseline within the 
metformin group was 
observed at 6 months (-3.4 
(95% ci: -5.3, -1.5) kg, 
P<0.05)
nct00151411
Hoeger (2015)92 Overweight/obese 
adolescents with PcOS
n.=36; age: 15.1±1.6 
years; BMi at baseline: 
38.0±8.0 kg/m2
PCOS definition: unknown
Metformin 2 g 











Pending analysis completion nct00283816
tfayli (2011)95 Overweight/obese 
adolescents with PcOS
n.=46; age: 16.0±0.3 
years; BMi at baseline: 
33.3±5.1 kg/m2
PCOS definition: 1990 
niH criteria




estradiol (ee) (3 
mg/30 µg) daily
Rosiglitazone significantly 
improved hepatic and 
peripheral insulin sensitivity
rosiglitazone was effective but 
inferior to drospirenone/ee in 
reducing hyperandrogenemia
rosiglitazone led to 
significantly decreased 
visceral adiposity, lower 
fasting and stimulated insulin 
levels during OGtt, lower 
triglycerides and higher 
adiponectin levels
drSP/ee treatment led to 
increased total cholesterol, 
high-sensitivity c-reactive 
protein and leptin 
concentrations
neither iMt nor PWv did 
change with any of the drugs
nct00640224
Frøssing (2018)96 Overweight/obese women 
with PcOS, BMi >25 
kg/m2 and/or presence 
of ir
n.=72; age: 29.9 [24.7-
34.2] years; BMi at 
baseline: 33.3±5.1 kg/m2




Placebo Liraglutide treatment 
significantly reduced body 
weight (-5.6%), liver fat 
content (-44%), vat (-18%) 
and naFLd prevalence 
(-75%) - all P<0.01
nct02073929
Long (2018)94 Overweight/obese women 
with PCOS, BMI ≥24 
kg/m2 and/or waist 
circumference ≥85 cm
n.=30 - expected; age: 14 
to 50 years
PCOS definition: 2003 
rotterdam criteria
Metformin 1.5 g 
+ exenatide 10 
µg daily Or 
metformin 1.5 g + 
liraglutide 1.8 mg 
daily
Metformin 




data are presented as proportions, median [interquartile range] or mean±Sd, as appropriate.
GLP-1 ra: glucagon-like peptide receptor agonist; BMi: Body Mass index; nct: clinicaltrials.gov registration number; SHBG: sex hormone 
binding globulin; drSP: drospirenone; ee: ethynyl estradiol; iS: insulin sensitivity; ir: insulin resistance; iSi: insulin Sensitivity index; 
Hec: hyperinsulinemic euglycemic clamp; OGtt: oral glucose tolerance test; PWv: pulse wave velocity; iMt: intima media thickness; 
naFLd: nonalcoholic fatty liver disease; vat: visceral adipose tissue.
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tZd available on the market and currently rou-
tinely used for the treatment of type 2 diabetes 
is pioglitazone, which holds similar insulin-sen-
sitizing property without major adverse effects, 
except an increased rate of drug-induced fluid 
retention. Some reports have associated the use 
of pioglitazone with an increased risk osteopo-
rotic fractures and bladder cancer in individu-
als carrying additional predisposing genetic and 
environmental co-factors. a teratogenic risk of 
tZds prevents their prescription in women de-
siring pregnancy.110 as a result, large interven-
tional trials in PcOS are lacking and data on 
adolescents are limited95, 111 (table ii). Hence, 
given the unfavorable risk-benefit ratio, TZDs 
are currently not recommended for treatment 
in PcOS.17 However, they can be considered 
for use in selected cases of women not seek-
ing pregnancy, intolerant to metformin and with 
symptoms and signs of PcOS poorly controlled 
by other established therapies.
GLP-1 receptor agonists
Glucagon-like peptide 1 receptor agonists (GLP-
1 ras) represent a relatively recent class of 
drugs, currently approved for the treatment of 
diabetes mellitus, that exert a glucose-lowering 
effect by combining reduced gastric emptying, 
increased satiety, regulation of hypothalamic and 
cerebral responses to feeding, improvement of 
glucose-dependent insulin secretion from pan-
creatic islets and have other multifaceted effects 
on the liver, skeletal muscle and adipocytes that 
eventually lead to improved glucose homeosta-
sis and more favorable lipid profiles. Since the 
earliest registration trials, GLP-1 ras have been 
shown to be effective in reducing whole-body 
IR, primarily due to significant and consistent 
improvements in body weight and visceral fat 
content since treatment initiation.112 Given the 
beneficial effects on many factors contributing to 
ir, and having a negligible risk of hypoglycemia, 
GLP-1 ras represent an attractive treatment op-
tion to manage the various aspects of ir, includ-
ing PcOS. in a 24-week open label trial involv-
ing 60 obese adult women with PcOS, the com-
bination of the GLP-1 ra exenatide (10 µg/day) 
with metformin (2 g/day) improved menstrual 
However, it should be kept in mind that the pos-
sible long-term positive effect of metformin on 
the cardiovascular risk profile shown in other 
hallmark studies,97 would play in favor of an ear-
ly use also in subjects with PcOS, in whom ther-
apeutic LSM are impracticable or ineffective. 
The evidence of beneficial effects of metformin 
on hyperandrogenism (including acne alopecia, 
hirsutism), menses abnormalities, infertility and 
live birth rates in young women with PcOS is 
very limited93, 98 and should be matter of further 
investigation.94 Finally, when it comes to weigh 
benefits against potential side effects, it should 
be borne in mind that 25% of individuals treated 
with metformin suffer of gastro-intestinal, dose-
dependent side effects (mainly diarrhea and gas-
tric spasms), which, despite proper dose tapering 
may eventually lead to therapy discontinuation.99 
the mechanisms responsible for metformin in-
tolerance lack of conclusive evidence, although 
it is hypothesized that high concentrations may 
induce increased of serotonin production from 
enterochromaffin cells in the gut, particularly 
in individuals carrying mutations in the Organic 
cation transporter (Oct) and Serotonin trans-
porter (Sert) loci.100, 101
Thiazolidinediones
thiazolidinediones (tZds) are “insulin sensitiz-
ers” that have been demonstrated to be effective 
in some aspects of PcOS. tZds are peroxi-
some proliferator–activated receptor gamma 
(PPAR-γ) agonists. PPAR-γ represents a nuclear 
receptor family of ligand-inducible transcrip-
tion factors primarily expressed in the liver and 
skeletal muscle and involved in the regulation of 
adipogenesis, lipid metabolism, cell prolifera-
tion, inflammation and insulin sensitivity.102, 103 
When used alone or in combination with estro-
progestinic drugs, tZds have dose-dependent 
beneficial hormonal and metabolic effects in 
adult women with PcOS, including improve-
ment of ovulatory dysfunction, hirsutism, hy-
perandrogenemia, and ir.104-108 among the ac-
tive principles developed so far, troglitazone and 
rosiglitazone have been removed from the mar-
ket due to reports of idiosyncratic liver toxicity 
and increased cardiovascular events.109 the only 
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cyclicity, ovulation rate, androgen levels, insu-
lin sensitivity measures, abdominal fat content 
and weight loss, as compared with exenatide and 
metformin used as single therapies.113 Hormonal 
and reproductive effects appeared to be medi-
ated by the decreased insulin levels, although 
mechanistic insights regarding a direct effect of 
GLP-1 and related gastrointestinal peptides on 
the hypothalamic-pituitary-adrenal axis have 
been recently postulated.40 However, this study 
had a relatively high drop-out rate (nearly 30%) 
and the limited duration did not allow to general-
ize the observations and did not provide any cue 
on the long-term efficacy of the combined GLP-
1 ra-metformin therapy. More recently, add-on 
liraglutide (1.2 mg/day) has been reported to be 
effective in reducing body weight in a 12-week, 
open label, prospective study involving 40 obese, 
adult women with PcOS, who had been pre-
treated with metformin for at least 6 months.114 
this study was, however, affected by the limited 
sample size and the unblinded treatment assign-
ment96 (table ii). Gastrointestinal intolerance, in-
cluding nausea and vomiting, represents the most 
frequent and well-known side effect of GLP-1 
ra therapy, which may be improvement by care-
ful stepwise dose titration. the current availabil-
ity of extended release formulations of GLP-1 
ra will represent a new opportunity to explore 
their effects on metabolic and fertility outcomes 
of PcOS. indeed, long-acting GLP-1 ra formu-
lations are characterized by a considerably bet-
ter tolerability profile, which would reduce side 
effects and favor overall treatment compliance. 
The current level of evidence is not sufficient to 
support a wide use of GLP-1 ra in PcOS, al-
though it seems reasonable to forecast the po-
tential therapeutic use of GLP-1 ra primarily in 
obese PcOS women.115 therefore, further larger 
double-blinded, randomized trials of longer du-
ration are warranted. adolescents/young adults 
unfortunately, still remain under-represented in 
PcOS trials.
Inositols
new treatment strategies have been developed to 
improve insulin sensitivity in PcOS, and among 
these, inositols are becoming increasingly attrac-
tive. inositols are natural compounds contained 
in many plants and foods and are mainly synthe-
tized in humans from d-glucose in two inositol 
stereoisomers: myo-inositol (MYO) and d-chiro-
inositol (dci).116, 117 MYO is the precursor of the 
second messenger inositol triphosphate (iP3), 
which is involved in insulin, follicle-stimulating 
hormone (FSH) and thyroid-stimulating hormone 
(tSH) signalling pathways. Moreover, additional 
roles have been evidenced for MYO as the abil-
ity to counteract oxidative stress118 and reduce 
ovarian stromal blood flow.119 red blood cells 
(rBcs) from PcOS women have been reported 
to be more sensitive to oxidative injuries, and an 
in-vitro study showed that some of these abnor-
malities were restored after 12 weeks of treatment 
with MYO.118 dci is a derivative of MYO which 
is synthesized via an insulin-dependent pathway 
by an epimerase.120, 121 dci decreases aspartate 
transaminase (aSt), alanine transaminase (aLt), 
reduces inflammation and attenuates oxidative 
stress in treated cholestatic rats.122 MYO and dci 
are physiologically present in plasma in a 40:1 ra-
tio123 and both act as insulin sensitizers.124 MYO 
supports cellular glucose intake and dci promotes 
glycogen synthesis.125 an interesting study dem-
onstrated that in the endometrium from insulin-re-
sistant obese PcOS patients, sodium-myoinositol 
cotransporter-1 (SMIT-1), a specific MYO trans-
porter, was reduced, thus limiting MYO uptake 
in endometrial cells.126 in this same study, in an 
endometrial stromal cell line simulating a PcOS-
like condition by exposing the cells to t, insulin 
and tumor necrosis factor alpha (TNFα), AMPK 
activation was found to be reduced and was re-
stored after the administration of MYO con-
firming its insulin-sensitizing effect. Noticeably, 
also glucose transporter type 4 (GLUt-4) lev-
els, which were decreased in the PcOS-induced 
condition, were restored after MYO administra-
tion.126 these results were similar to those found 
using metformin as insulin-sensitizing agent in 
the same in-vitro conditions.126 as myo-inositol 
oxygenase (MIOX) is the first enzyme involved in 
MYO catabolism it was hypothesized that it could 
be altered in PcOS patients leading to MYO de-
ficiency, however, a recent study reported that 
this enzyme was unchanged in serum from PcOS 
subjects excluding its role in MYO deficiency, 
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bioavailability, seems to be promising. One study 
reports that in 14 out of 37 PcOS patients resis-
tant to treatment, the association of MYO (2 g) 
with α-LA (50 mg) twice daily for 3 months re-
stored ovulation in 86% of the patients.136
MYO has been studied in combination with ty-
rosine, selenium and chromium treatments also, 
and the efficacy has been reported in relationship 
with the different PcOS phenotypes.137 in detail, 
in this study, 186 PcOS patients were divided 
in 4 groups based on clinical and biochemical 
parameters. the administration of MYO (2 g), 
L-tyrosine (0.5 mg), folic acid (0.2 mg), sele-
nium (55 µg), and chromium (40 µg) daily for 6 
months restored ovulation in 65% of the patients 
belonging to the phenotypic group characterized 
by androgen excess, ovulatory dysfunction and 
PcOS morphology. Glucose and HOMa-ir im-
proved too. in the group with androgen excess 
and ovulatory dysfunction, 80% of patients ovu-
lated after six months on treatment and clinical 
and biochemical hyperandrogenism improved. 
in the group characterized by androgen excess 
and PcOS morphology a decrease in BMi was 
observed also. Finally, in the group with ovula-
tory dysfunction and PcOS morphology, 60% of 
the women regularized their menstrual periods 
and ovulated. the combined daily treatment of 
MYO (2 g), with gymnemic acid (75 mg) and L-
methylfolate (400 µg) was compared with treat-
ment with MYO (2 g) and folic acid (400 µg) in 
100 PcOS patients for 6 months. Gymnemic acid 
is structurally similar to glucose and is involved 
in glucose homeostasis.138 L-methylfolate is a 
natural folate that is used to reduce hyperhomo-
cysteinemia and increases insulin sensitivity.138 
the combined treatment was more effective in 
improving BMi, menstrual cycle regularity, gly-
cemia and insulinemia. Furthermore, the combi-
nation decreased t, total cholesterol and homo-
cysteine levels while SHBG increased.138 the 
administration of MYO in combination with dci 
in different ratios has been also evaluated. this 
treatment was hypothesized based on the belief 
that in the PcOS ovary the MYO/dci ratio is al-
tered.120, 121 Since the insulin-responsive tissues 
present a specific ratio MYO/DCI, the physi-
ological balance might be restored.124 the most 
recent studies concerning the combined treat-
opening a view on alternative ways of clear-
ance of MYO from the body.127 recent reviews 
extensively documented the emerging roles of 
inositols in PcOS treatment.128-131 Here the most 
recent clinical and laboratory studies have been 
reported (table iii).123, 132-143 a meta-analysis of 
10 rcts, reported the effects of MYO treatment 
in PcOS in 573 patients showing that MYO im-
proved HOMa-ir, increased e2, and slightly re-
duced t levels.132 another meta-analysis includ-
ing 6 randomized clinical trials compared MYO 
with metformin treatment in 355 PcOS patients. 
the analysis evidenced no differences between 
the two treatments relative to the effects on fast-
ing insulin, HOMa-ir, BMi, t, SHBG, as well 
as on other hormonal levels. an increased risk of 
adverse events was reported in women receiving 
metformin, and MYO had a better tolerability.133 
Furthermore, a recent study on 53 women with 
PcOS compared MYO with metformin to evalu-
ate their role in glycemic control, insulin and lipid 
metabolism. Patients were randomly treated with 
MYO or metformin for 3 months; fasting plasma 
glucose, insulin, and HOMa-ir as well as se-
rum triglycerides and vLdL-cholesterol were 
reduced by MYO treatment. Furthermore, MYO 
treatment increased PPAR-γ expression, a key 
regulator of adipocyte differentiation, fat storage, 
and energy homeostasis.134 the evaluation of the 
effects of 4 g MYO+400 µg folic acid alone or 
in combination with an oral contraceptive pill 
(OcP) containing drospirenone in a population of 
61 adolescents with PcOS led to important results 
concerning the prevention and correction of meta-
bolic disorders. in particular, the treatment with 
MYO reduced body weight and BMi, as well as 
blood glucose, insulin, HOMa-ir, and c-peptide. 
MYO reduced also hormonal parameters such as 
t and luteinizing hormone (LH). the treatment 
with OcP increased slightly weight and BMi, and 
the combination with MYO and OcP reduced in-
sulin, HOMa-ir and c-peptide. With regard to 
hormonal parameters, the combined treatment led 
to a decrease in t, Fai, dHea-S, LH and aMH 
and to an increase in SHBG thus enhancing anti-
androgenic effects.135 Besides these results, some 
PcOS patients seem to be resistant to MYO; in 
these patients combining MYO with alpha-lact-
albumin (α-LA), a molecule that increases MYO 
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Table III.— Main findings relative to studies using inositols as single treatment or in association with other treat-
ments.123, 132-143
Study Subjects drug comparator Main results
Zeng (2018)132 normal/overweight/obese 
PcOS patients included in 10 
randomized controlled trials
n.=573; age: from 13 to 38 years
BMi >30 kg/m2 (3 studies)
25 <BMI<30 kg/m2 (3 studies)
BMI <25 kg/m2 (3 studies)
BMi not reported (1 study)
PCOS definition: unknown
MYO 0.55 g + dci 
0.0138 g + folic 
acid 200 µg twice 
daily Or MYO 
from 1.2 g to 4 g 
+ folic acid from 
200 µg to 400 µg 
daily Or MYO 
from 0.2 g to 2 g 
Or MYO 4 g + 
folic acid 400 µg 
+ drSP 3 mg/ ee 
30 µg daily
Placebo Or folic acid 
from 200 µg to 400 µg 
daily Or metformin 1.5 
g daily Or drSP 3 mg/ 
ee 30 µg daily
improvement in HOMa-ir
increase in e2 levels




patients included in 6 
randomized controlled trials
n.=355; age: from 15 to 45 years
Mean BMi >25 kg/m2 except for 
1 study on normal-weighted 
subjects
PCOS definition: 2003 Rotterdam 
criteria or androgen excess 
Society Guidelines
MYO from 2 g to 4 
g daily
Metformin from 1.5 g to 
2 g daily
no differences between the two 
treatments relative to fasting insulin, 
HOMa-ir, BMi, testosterone, 
SHBG and other hormonal levels
increased risk of adverse side effects 
under Met treatment




n.=53; age: from 18 to 40 years
BMi at baseline:
MYO group: 28.1±3.1 kg/m2
Met group: 27.3±3.3 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO 4 g + folic 
acid 400 µg daily
Metformin 1.5 g daily reduction in FPG, insulin, HOMa-
ir, serum triglycerides and vLdL-
cholesterol and increase in PPAR-γ 






n.=61; age: from 13 to 19 years
BMi at baseline:
MYO group: 22.3±3.08 kg/m2
MYO+OcP group: 22.24±3.26 
kg/m2
OcP group: 22.74±3.75 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO 4 g + folic 
acid 400 µg daily
Or
MYO 4 g + folic 
acid 400 µg + 
drSP 3 mg/ ee 
30 µg daily
drSP 3 mg/ ee 30 µg 
daily
reduction of weight, BMi, blood 
glucose, insulin, HOMa-ir, 
c-peptide, testosterone, LH under 
MYO treatment alone
Slight increase in weight and BMi 
under drSP/ee treatment
reduction of insulin, HOMa-ir 
and c-peptide, testosterone, Fai, 
dHea-S, LH, aMH, and increase 






n.=37; age: 27.1±2.4 years
BMi: 25.9±1.2 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO 4 g + 
α-lactalbumin 
100 mg daily
MYO 4 g daily restoration of ovulation in 86% of 






n.=186; age: from 16 to 38 years
BMi at baseline:
Phenotype a: 26.52±3.67 kg/m2
Phenotype B: 26.39±5.09 kg/m2
Phenotype c: 25.84±3.13 kg/m2
Phenotype d: 26.52±2.98 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO 2 g + 
L-tyrosine 0.5mg 
+ folic acid 0.2 
mg + selenium 5 
µg + chromium 
40 µg daily
Baseline with no treatment Phenotype a (androgen excess, 
ovulatory dysfunction, PcO 
morphology): restoration of 
ovulation in 65% patients, 
improvement in glucose levels and 
HOMa-ir
Phenotype B (androgen excess, 
ovulatory dysfunction): restoration 
of ovulation in 80% patients, 
improvement in clinical and 
biochemical hyperandrogenism
Phenotype c (androgen excess, PcO 
morphology): decrease in BMi
Phenotype d (ovulatory dysfunction, 
PcO morphology): restoration of 
ovulation in 60% patients
 (To be continued) 
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Table III.— Main findings relative to studies using inositols as single treatment or in association with other treat-
ments.123, 132-143






MYO+gym+L-met group: 27±3 
years
MYO group: 28±4 years
BMi at baseline:
MYO+gym+L-met group: 27±0.8 
kg/m2
MYO group: 27±0.9 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO 2 g + 
gymnemic 
acid 75 mg + 
L-methylfolate 
400 µg
MYO 2g + folic acid 
400 µg
Greater effectiveness of the 
combination in improving BMi, 
menstrual cycles, glycemia, and 
insulinemia
reduction of t, total cholesterol and 





n.=70; age: 28.4±5.1 years
BMi at baseline: >25 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO:dci in a 
10:1 ratio daily 
(total of 1100 g 
inositols) + of 
folic acid 400 µg 
+ vitamin d 1000 
iU + vitamin 
B6 1.4 mg + 
vitamin B5 6 mg 
+ vitamin B12 2.5 
µg twice a day
Baseline with no treatment reduction in body weight, t, FSH, 
LH, insulin, glucose levels
increase in SHBG
improvement of skin conditions
Benelli 
(2016)123
Obese young PcOS patients
n.=46
age:
treated group: 23±6.8 years
placebo group: 25±7.3 years
BMi at baseline:
treated group: 32±4.8 kg/m2
Placebo group: 31±4.6 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO:dci in a 
40:1 ratio (MYO 
550 mg + dci 
13.8 mg + 200 µg 
folic acid twice 
a day
Placebo: folic acid 200 µg 
twice a day
reduction in fasting insulin, HOMa-
ir, LH, and t
Increase in 17-β-estradiol and SHBG
nordio 
(2019)140
normal weighted PcOS patients
n.=56
age:
0:1 group: 30.5±2.9 years
1:3.5 group: 28.9±3.4 years; 2.5:1 
group: 29.3±3.1 years
5:1 group: 31.2±2.7 years
20:1 group: 30.6±3.0 years
40:1 group: 31.1±3.2 years
80:1 group: 29.7±2.8 years
BMi at baseline:
0:1 group: 23.48±3.0 kg/m2
1:3.5 group: 24.52±2.8 kg/m2
2.5:1 group: 22.87±2.9 kg/m2
5:1 group: 24.12±2.7 kg/m2
20:1 group: 23.21±3.1 kg/m2
40:1 group: 24.08±3.0 kg/m2
80:1 group: 22.98±2.9 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO/dci 2 g in 7 
different ratios: 
0:1, 1.3:5, 2.5:1, 
5:1, 20:1, 40:1, 
80:1 twice a day
nr the 40:1 ratio was the most effective 
in decreasing LH, postprandial 
insulin levels and increasing SHBG, 
e2, progesterone, and normalizing 
ovulation
A modification of the ratio in favor of 




Young overweight PcOS patients
n.=30
age:
PcOS group: 19.7±1.9 years
ctrL group: 21.9±2.9 years
BMi at baseline:
PcOS group: 28.4±1.7 kg/m2
ctrL group: 21.6±1.6 kg/m2
PCOS definition: 2003 Rotterdam 
criteria and adolescent criteria 
for the diagnosis of PcOS
MYO 1.75 g + 
dci 0.25 g + 
glucomannan 4 
g daily
Baseline with no treatment 
Or control group
Fifteen metabolites mainly involved 
in carbohydrate and lipid metabolic 
pathways were identified and 
discriminated PcOS from ctrL at 
baseline
a subgroup of these metabolites 
showed changes in PcOS patients 
after treatment
improvement in metabolism, BMi, 
menstrual cycles, the number of 
antral follicles, ovary volume, 
hirsutism, and acne under the 
combined treatment
 (To be continued) 
 (continues).
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17-β-estradiol (E2) and SHBG.123 to better clar-
ify the effectiveness of different ratios between 
MYO and dci a recent study evaluated 7 dif-
ferent combinations of ratios.140 a population of 
56 patients was subdivided into 7 groups treated 
with a MYO/dci ratio of 0:1, 1:3.5, 2.5:1, 5:1, 
20:1, 40:1, 80:1, respectively given twice daily 
for 3 months. the most effective formulation 
was the 40:1 ratio MYO/dci which decreased 
LH, and increased SHBG, e2, progesterone, and 
normalized ovulation. Furthermore, the 40:1 ra-
tio decreased basal and postprandial insulin lev-
els. Interestingly, a modification of the ratio in 
favor of dci determined a reduction in the ben-
eficial effects of treatment.140 these results were 
consistent with findings obtained in a PCOS 
mouse models where the 40:1 ratio was the most 
ment are reported hereafter. the combination of 
MYO and dci in a 10:1 ratio has been reported 
to be effective in improving metabolic and hor-
monal parameters in 70 women with PcOS after 
6 months on treatment.139 In particular, a signifi-
cant reduction in body weight, as well as a de-
crease in t, FSH and LH levels was reported after 
3 months on treatment and was confirmed after 
6. Furthermore, SHBG increased after 6 months 
on treatment while insulin and glucose levels 
decreased. the treatment improved skin condi-
tions also.139 in a group of 46 young obese PcOS 
an improvement of hormonal and metabolic pa-
rameters was observed. in detail, the combined 
treatment with MYO and dci in a 40:1 ratio for 
six months lead to a reduction in fasting insu-
lin, HOMa-ir, LH, and t, and an increase in 
Table III.— Main findings relative to studies using inositols as single treatment or in association with other treat-
ments.123, 132-143
Study Subjects drug comparator Main results
advani 
(2020)142




<21 yr: 17.50±0.50 years
21-25 years: 22.50±0.50 years
26-35 years: 30.00±0.88 years
>35 years: 36.50±0.50 years
Obese group
<21 years: 19.00±0.57 years
21-25 years: 23.00±0.70 years
26-35 years: 29.38±0.47 years
>35 years: 36.50±0.50 years
BMi at baseline:
Lean group: 21.88±0.30 kg/m2
Obese group: 27.03±0.56 kg/m2
PCOS definition: 2003 Rotterdam 
criteria
MYO:dci 600 mg 
+ nac 300 mg 
+ Biotin 5 mg + 
10% lycopene 5 
mg + chromium 
picolinate 200 
µg + folic acid 
120 µg + vitamin 
d 400 iU twice 
a day
Baseline with no treatment reduction in body weight and BMi in 
obese subjects
reduction of hirsutism and acne in 






Only diet group: 29.7±0.8 years





Only diet group: 31.9±5.2 kg/m2




PCOS definition: 2003 Rotterdam 
criteria
MYO 1.1 g + dci 
27.6 mg + folic 




Or MYO 4 g + folic acid 
400 µg + controlled diet 
daily
improvement in terms of body weight, 
BMi, waist and hip circumferences 
in all groups
restoration of menstrual cyclicity in 
the group treated with the combined 
treatment MYO + dci + folic acid 
+ controlled diet
PcOS: polycystic ovary syndrome; BMi: Body Mass index; MYO: myo-inositol; dci: d-chiro-inositol; drSP: drospirenone; ee: ethinyl 
estradiol; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; E2: 17-β-estradiol; SHBG: sex hormone binding globulin; 
MET: metformin; FPG: fasting blood glucose; VLDL: very low-density lipoprotein; PPAR-γ: peroxisome proliferator activated receptor 
gamma; OcP: oral contraceptive pill; Fai: Free androgen index; dHea-S: dehydroepiandrosterone sulfate; aMH: anti-Müllerian hormone; 
gym: gymnemic acid; L-met: L-methylfolate; t: testosterone.
 (continues).
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often is on a systemic basis. PcOS is also char-
acterized by chronic low-grade inflammation 
and patients have abnormal high levels of reac-
tive oxygen species (rOS).145 increased oxidant 
status appears to worsen in ir state.146 aLa is a 
potent natural antioxidant lipophilic compound, 
produced by plants and animals, and is a cata-
lytic factor for the oxidative decarboxylation of 
pyruvate and α-ketoglutarate. It acts as a pivotal 
cofactor for mitochondrial enzymes activity and 
favors the efficacy of other antioxidants such as 
glutathione.147 aLa, similarly to insulin, plays a 
role in the regulation of glucose and lipid metab-
olism by stimulating glucose uptake through an 
intracellular redistribution of glucose transporter 
type 1 (GLUt-1) and GLUt-4 glucose transport-
ers.148 aLa has been demonstrated to stimulate 
glucose utilization through the increase of aMP) 
in skeletal muscles increasing GLUt-4.149, 150 
Growing evidence suggests that aLa may im-
prove reproductive function and metabolic pa-
rameters (table iv).146, 151-157 a controlled-re-
lease aLa preparation at a high daily dosage of 
1200 mg (600 mg twice daily) was administered 
for 16 weeks to normal weight (BMi: 18.5 to 
26.6 kg/m2), non-diabetic PcOS young women 
(age 23 to 34 years). A significant improvement 
in insulin sensitivity was described by the eug-
lycemic, hyperinsulinemic clamp gold standard 
technique, and an improvement in menstrual 
cyclicity was reported also. A significant reduc-
tion in triglyceride levels was further reported, 
although no change in the distribution of the li-
poprotein fractions was measured. Moreover, no 
change in circulating oxidative stress markers 
was detected.151 in a recent observational study 
aLa was administered at a low dosage (400 mg 
daily) for 12 weeks in obese (BMi >25 kg/m2) 
young PcOS patients (24.5±1.3 years). among 
these patients, about 62% reported to have a type 
1 or 2 diabetes familiarity. treatment reduced 
significantly insulin, glucose, BMI and HOMA-
ir. in particular, the PcOS patients with dia-
betic relatives showed a reduction in triglycer-
ides and aSt as well. interestingly, in all PcOS 
patients no changes occurred on all hormonal 
parameters associated with fertility such as LH, 
FSH, and androstenedione.152 administration of 
aLa combined with inositols was recently used 
effective in reverting PcOS phenotype in terms 
of theca/granulosa cell layer thickness.144 a com-
bined treatment of MYO (1.75 g), dci (0.25 g) 
and glucomannan (4 g) daily for 3 months was 
investigated in a population of PcOS patients 
using a metabolomic approach. Glucomannan is 
a vegetal compound which inhibits cholesterol 
synthesis in liver and enhances its clearance, and 
in addition gives a feeling of satiety. a group of 
15 metabolites, mainly involved in carbohydrate 
and lipid metabolic pathways, were identified 
and discriminated cases from controls at base-
line, and a subgroup of these metabolites showed 
changes in the PcOS patients after treatment. 
Furthermore, the combined treatment improved 
metabolism, BMi, menstrual cycles, the num-
ber of antral follicles, ovary volume, hirsutism 
and acne.141 MYO and dci in combination with 
antioxidants (n-acetylcysteine and lycopene), 
chromium picolinate and vitamins (vitamin d, 
biotin and folic acid) were used in a very recent 
observational study. these compounds were ad-
ministered to 35 obese and 16 lean PcOS pa-
tients revealing a reduction in body weight and 
BMi in obese subjects. Furthermore, this treat-
ment reduced hirsutism and acne both in lean 
and obese PcOS patients.142 Other studies have 
focused more on clinical and body composition 
outcomes in PcOS associated with overweight 
and obesity. a recent study in 43 PcOS patients, 
subdivided the women in 3 groups that were re-
evaluated after 6 months of treatment: the first 
group underwent a controlled diet only, the sec-
ond group was treated with controlled diet and 
MYO (4 g) and folic acid (400 µg) daily in ad-
dition, and the third group with controlled diet 
and MYO (1.1 g), dci (27.6 mg) and folic acid 
(400 µg) daily in association. Body composition 
in terms of body weight, BMi, waist and hip cir-
cumferences improved in all groups. However, 
only the administration of the combined treat-
ment MYO+dci was effective in the restoration 
of menstrual cyclicity.143
Alpha-lipoic acid
emerging data in the Literature support alpha-li-
poic acid (aLa) as another compound effective 
in treating insulin resistant conditions, as PcOS 
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Table IV.— Main findings relative to studies using alpha-lipoic acid as single treatment or in association with inosi-
tols.146, 151-157
Study Subjects drug comparator Main results
Masharani 
(2010)151
non-obese women with PcOS
n.=6
age: from 23 to 34 years
BMi at baseline: from 18.5 to 26.6 kg/m2; 
mean 22±1.4 kg/m2
PCOS definition: Rotterdam Criteria
crLa 600 mg twice 
daily for 16 weeks
Baseline with 
no treatment
improvement in insulin sensitivity and 
in menstrual cyclicity. reduction 
in triglyceride levels. no change in 
the distribution of the lipoprotein 




Obese PcOS patients with PcOS
n.=32
age: 24.5±1.3 years
BMi at baseline: 32.5±1.9 kg/m2
PCOS definition: American Society for 
reproductive Medicine and the european 
Society for Human reproduction and 
embryology consensus meeting to 
diagnose the presence of PcOS
aLa 400 mg per os 




insulin, glucose, BMi and HOMa-
ir were reduced. a reduction in 
triglycerides and aSt. no changes 
occurred on all hormonal parameters 




Women of reproductive age with vs without 
PcOS
n.=46: 26 vs. 20
age: from 16 to 32 years; mean 23.8±2.5 
years
BMi at baseline: 33.3±5.1 kg/m2
PCOS definition: Rotterdam Criteria
dci 1000 mg + aLa 
600 mg daily Or 
untreated







improvement in HOMa-ir index, 
insulin levels, frequency of menstrual 
cycles and ovulation. reduction in 
ovarian cyst count and BMi
Fruzzetti 
(2019)153
Women of reproductive age with vs. 
without PcOS.
n.=71: 41 vs. 30
age: from 18 to 30 years; mean 22.3±5.0 
vs. 23.1±5.4 years
BMi at baseline: 26.2±5.3 vs. 27.2±3.9 kg/
m2
PCOS definition: Rotterdam Criteria
aLa 600 mg + dci 







cycle length reduced after treatment. 
BMi, after an initial reduction at 6 
months on treatment, returned to 
the baseline. HOMa-ir and fasting 
insulin unchanged, but insulin 
response to OGtt improved
de cicco 
(2017)154
Overweight–obese women with PcOS
n.=40
age: from 18 to 35 years; mean 25.57±5.72 
years
BMi at baseline: 30.03±4.47 kg/m2
PCOS definition: Rotterdam Consensus 
conference criteria
aLa 800 mg + MYO 




improved frequency of menses. 
Free androgen index, mean 
androstenedione and dHeaS levels 
were lowered, SHBG levels increased, 
hirsutism and BMi improved, aMH, 
ovarian volume and number of total 
antral follicular diminished. no 




Women of reproductive age with vs without 
PcOS
n.=74: 44 vs. 30
age: 21±4.7 vs. 23.1±5.4 years
BMi at baseline: 27.05±4.17 vs. 27.17±3.93 
kg/m2
PCOS definition: Rotterdam Criteria
aLa 800 mg + MYO 
2000 mg per day 
divided into two 
oral administrations 







improvement in menstrual cycle length, 
restoration of ovulation, reduction 
in BMi. no change in the HOMa-
ir index, and in insulin levels. in 
the women with insulin resistance, 
HOMa-ir and insulin decreased at 




Women of reproductive age with PcOS
Group a: n.=24; BMi at baseline: 28.4±1.7 
kg/m2
Group B: n.=24; BMi at baseline: 32.8±1.7 
kg/m2
Group c: n.=28; BMi at baseline: 29.8±1.5 
kg/m2
age: 25.6±1.3 years
PCOS definition: ESHRE Criteria
Group a: MYO 1 g/
day per os for 12 
weeks
Group B: aLa 400 
mg/day per os for 
12 weeks
Group c: MYO 1 g/
day + aLa 400 mg/




MYO improved reproductive hormones 
and reduced insulin levels in response 
to OGtt in PcOS patients with 
no family history of diabetes; aLa 
reduced insulin levels in response 
to OGtt and metabolic parameters; 
MYO + aLa improved both hormonal 
and metabolic parameters and reduced 




Women of reproductive age with vs. 
without PcOS
n.=44: 23 vs. 21
age: 17.22±0.72 vs. 16.97±0.63 years
BMi at baseline: 27.51±1.15 vs. 23.19±1.52 
kg/m2
PCOS definition: Rotterdam Criteria
aLa 400 mg + MYO 
1 gr twice daily for 
3 months and once 







HMGB1 increased in PcOS and 
normalized after treatment. treatment 
reduced insulin, HOMa-ir and 
17-OHP
PcOS: polycystic ovary syndrome; BMi: Body Mass index; crLa: controlled-release alpha-lipoic acid; aLa: alpha-lipoic acid; MYO: myo-
inositol; dci: d-chiro-inositol; HOMa-ir: Homeostatic Model assessment for insulin resistance; aSt: aspartate aminotransferase: LH: 
luteinizing hormone: FSH: follicle-stimulating hormone: dHea-S: dehydroepiandrosterone sulfate; aMH: anti-Müllerian hormone; OGtt: 
oral glucose tolerance test; 17-OHP: 17-hydroxyprogesterone; SHBG: sex hormone binding globulin.
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as a dietary supplement in insulin-resistant pa-
tients as both increase insulin sensitivity (table 
iv). in a long-term prospective study, a com-
bination of aLa and dci (600 mg aLa and 
1000 mg dci) was administered for 6 months 
daily to PcOS women of reproductive age. Fol-
lowing treatment, a significant improvement 
in the HOMa-ir index and insulin levels was 
observed in addition with improvement in the 
frequency of menstrual cycles and ovulation. in 
addition, a reduction in ovarian cyst count and 
BMi was reported.146 a further recent study used 
the same combination of aLa and dci as in this 
previous study, including a heathy control group 
matched for age and BMi, and observed an im-
provement in menstrual cycle length, restored 
ovulation in most, a reduction in BMi but no 
significant change in the HOMA-IR index, and 
in insulin levels. However, in the women with 
IR, HOMA-IR and insulin decreased signifi-
cantly at variance with the women with normal 
insulin sensitivity.153 a pilot cohort study used 
a combination of aLa and MYO (800 mg aLa 
and 2000 mg MYO) given daily for six months 
to overweight-obese PcOS women only. Fol-
lowing treatment PcOS patients reported a sig-
nificant increase in the frequency of menses. The 
free androgen index (Fai), the mean androstene-
dione and dHea-S levels were lowered sig-
nificantly, SHBG levels significantly increased, 
hirsutism and BMi improved, aMH, ovarian 
volume and number of total antral follicular di-
minished. no change in glucose, insulin or lipid 
parameters was observed.154 a further long-term 
retrospective study reported on the effects of a 
combined treatment with aLa and MYO (800 
mg of aLa + 2000 mg of MYO) administered 
daily for 24 months to a group of young normal 
weight PcOS women. a healthy control group 
matched for age and BMi was included. cycle 
length was significantly reduced after treat-
ment. BMi, after an initial reduction at 6 months 
on treatment, returned to the baseline levels; 
HOMa-ir and fasting insulin were unchanged, 
but the insulin response to oral glucose tolerance 
test (OGtt) was improved.155 in a recent retro-
spective study, the effects of aLa alone (400 mg 
daily), MYO alone (1 g daily) and a combina-
tion of aLa + MYO (400 mg of aLa + 1 g of 
MYO daily) were evaluated in overweight/obese 
young PcOS patients after 3 months of treat-
ment. MYO improved reproductive hormones 
and reduced insulin levels in response to OGtt 
in PcOS patients with no family history of dia-
betes; aLa reduced insulin levels in response to 
OGtt and metabolic parameters in all patients; 
MYO + aLa improved both hormonal and met-
abolic parameters and reduced insulin levels in 
response to OGtt in all patients.156 in a further 
recent observational study, a combination of 
aLa (400 mg) + MYO (1 g) taken twice daily 
for 3 months and once daily for further 3 months 
was administered to adolescents with PcOS. 
this combined treatment was effective on high 
mobility group box 1 (HMGB1), a small protein 
involved in both inflammation and hyperglyce-
mia/ir. in particular, HMGB1 was increased 
in PcOS compared with controls and normal-
ized after treatment. Moreover, the treatment 
reduced insulin, HOMa-ir and 17-hydroxypro-
gesterone.157 Globally, data relative to the use of 
aLa alone or in combination with inositols are 
encouraging, however, data are still scarce and 
incomplete as the few studies differ with regard 
to study population (age, BMi), dosage, type and 
associations of molecules containing aLa. very 
few studies, have been conducted in adolescents. 
Most studies include adult women with an age 
range over 18 years. additional studies are re-
quired on adolescent women, in order to assess 
the effectiveness of diet supplements (nutraceu-
tical approach) in preventing negative impacts 
of PcOS on fertility in adult age.
Conclusions
current treatment of PcOS is increasingly mov-
ing towards treatments that consider the mecha-
nisms leading to the clinical and biochemical 
changes that characterize and complicate over 
time this syndrome. thus, whereas initially the 
correction of symptoms with LSM interventions 
and the use of Ocs represented the mainstay, 
the use of metformin and new insulin sensitiz-
ers, and among these latter nutraceutical agents 
is increasing and promising as they have an ef-
fect both on insulin sensitivity and inflammation, 
and ultimately on androgen production. there 
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20. Witchel SF, Oberfield SE, Peña AS. Polycystic Ova-
ry Syndrome: Pathophysiology, Presentation, and treat-
ment With emphasis on adolescent Girls. J endocr Soc 
2019;3:1545–73. 
21. Lim SS, davies MJ, norman rJ, Moran LJ. Overweight, 
obesity and central obesity in women with polycystic ovary 
syndrome: a systematic review and meta-analysis. Hum re-
prod Update 2012;18:618–37. 
22. tosi F, di Sarra d, Kaufman JM, Bonin c, Moretta r, 
Bonora e, et al. total body fat and central fat mass indepen-
dently predict insulin resistance but not hyperandrogenemia 
in women with polycystic ovary syndrome. J clin endocrinol 
Metab 2015;100:661–9. 
23. Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the 
phenotype and prevalence of obesity in polycystic ovary syn-
drome. J clin endocrinol Metab 2013;98:e1088–96. 
24. tosi F, Bonora e, Moghetti P. insulin resistance in a large 
cohort of women with polycystic ovary syndrome: a compari-
son between euglycaemic-hyperinsulinaemic clamp and sur-
rogate indexes. Hum reprod 2017;32:2515–21. 
25. cassar S, Misso ML, Hopkins WG, Shaw cS, teede HJ, 
Stepto nK. insulin resistance in polycystic ovary syndrome: 
a systematic review and meta-analysis of euglycaemic-hyper-
insulinaemic clamp studies. Hum reprod 2016;31:2619–31. 
26. tosi F, negri c, Perrone F, dorizzi r, castello r, Bonora 
e, et al. Hyperinsulinemia amplifies GnRH agonist stimulated 
ovarian steroid secretion in women with polycystic ovary syn-
drome. J clin endocrinol Metab 2012;97:1712–9. 
27. tosi F, negri c, Brun e, castello r, Faccini G, Bonora 
e, et al. insulin enhances actH-stimulated androgen and 
glucocorticoid metabolism in hyperandrogenic women. eur J 
endocrinol 2011;164:197–203. 
28. nestler Je, Powers LP, Matt dW, Steingold Ka, Plymate 
Sr, rittmaster rS, et al. a direct effect of hyperinsulinemia 
on serum sex hormone-binding globulin levels in obese wom-
is increasing evidence for the use of nutraceu-
tical agents that are devoid of the side-effects. 
Unfortunately, we are still missing significant 
studies in adolescents. this represents the most 
important age, as if PcOS were fully understood, 
treatment acting on the etiological causes would 
be more effective and would prevent full-blown 
pictures and the subsequent risk of infertility.
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